{"cik":1540171,"taxonomy":"us-gaap","tag":"AllocatedShareBasedCompensationExpense","label":"Share-based Payment Arrangement, Expense","description":"Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.","entityName":"Avalyn Pharma Inc.","units":{"USD":[{"start":"2025-01-01","end":"2025-03-31","val":543000,"accn":"0001193125-26-254623","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-06-03","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":1671000,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2025-04-01","end":"2025-06-30","val":1128000,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2025Q2"},{"start":"2025-01-01","end":"2025-09-30","val":2396000,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12"},{"start":"2025-07-01","end":"2025-09-30","val":725000,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12","frame":"CY2025Q3"},{"start":"2026-01-01","end":"2026-03-31","val":1193000,"accn":"0001193125-26-254623","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-06-03","frame":"CY2026Q1"},{"start":"2026-01-01","end":"2026-06-30","val":3983000,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2026-04-01","end":"2026-06-30","val":2790000,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2026Q2"},{"start":"2026-01-01","end":"2026-09-30","val":7079000,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12"},{"start":"2026-07-01","end":"2026-09-30","val":3096000,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12","frame":"CY2026Q3"}]}}